TREATMENT APPROACH FOR JUVENILE IDIOPATHIC ARTHRITIS-RELATED UVEITIS: 2012 UPDATE

Chronic anterior uveitis is the most common extra-articular complication of juvenile idiopathic arthritis. It is more frequent in the early onset forms with a higher prevalence in the oligoarticular (40%) than in other juvenile idiopathic arthritis subtypes (5–14%). The risk for severe visual impairment is still high due to the development of sight-threatening complications (synechiae, band keratopathy, cataract, glaucoma, cystoid macular oedema. Treatment is not standardized and requires a complex decision-making process, involving a close collaboration between paediatric ophthalmologist and rheumatologist. Topical therapy alone is often inadequate to control ocular inflammation and bulbar injections are too invasive to perform in children therefore immunosuppressive treatment is often advocated. Low dose methotrexate is the second-line agent mostly used although no controlled studies comparing effects of early to late methotrexate treatment have been reported. Mycophenolate mofetil is effective in controlling inflammation in methotrexate -refractory patients. Its efficacy, however, seems to be more relevant in intermediate or posterior uveitis, than in juvenile idiopathic arthritis uveitis and scleritis. Anti-TNFα agents, namely infliximab and adalimimab showed effectiveness in open-label studies but no wide controlled trials have been reported so far. Adalimimab is as effective as infliximab but has an easier way of administration and a better drug tolerance. Abatacept should be used in anti-TNF refractory patients with juvenile idiopathic arthritis uveitis.

1. Saurenmann R. K., Levin A. V., Feldman B. M., Rose J. B., Laxer R. M., Schneider R., Silverman E. D. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow up study. Arthritis Rheum. 2007; 56 (2): 647–657.

2. Zulian F., Martini G., Falcini F., Gerloni V., Zannin M. E., Pinello L. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J. Rheumatol. 2002; 29: 2446–2453.

3. Heiligenhaus A., Niewerth M., Ganser G., Heinz C., Minden K. German uveitis in childhood study group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a populationbased nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007; 46 (6): 1015–1019.

4. Edelsten C. Reconsidering treatment options in childhood uveitis. Br. J. Ophthalmol. 2007; 91 (2): 133–134.

5. Chylack L. T., Jr. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977; 20 (2): 217–223.

6. Duguid I. G., Ford R. L., Horgan S. E., Towler H. M., Lightman S. L. Combined orbital floor betamethasone and depot methyl pred nisolone in uveitis. Ocul. Immunol. Inflamm. 2005; 13 (1): 19–24.

7. Ferrante P., Ramsey A., Bunce C., Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub- Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin. Experiment. Ophthalmol. 2004; 32: 563–568.

8. Sallam A., Comer R. M., Chang J. H., Grigg J. R., Andrews R., McCluskey P. J. et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch. Ophthalmol. 2008; 126 (2): 200–205.

9. Suarez-Figueroa M., Contreras I., Noval S. Side-effects of triamcinolone in young patients. Arch. Soc. Esp. Oftalmol. 2006; 81 (7): 405–407.

10. Nguyen Q.D., Foster C. S. Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis. JAMA. 1998; 280 (13): 1133–1134.

11. Jabs D. A., Rosenbaum J. T., Foster C. S. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory diseases: recommendations from an expert panel. Am. J. Ophthalmol. 2000; 130: 492–513.

12. Wong V. G. Methotrexate treatment of uveal disease. Am. J. Med. Sci. 1966; 251: 239–241.

13. Bom S., Zamiri P., Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul. Immunol. Inflamm. 2001; 9 (1): 35–40.

14. Samson C. M., Waheed N., Baltatzis S., Foster C. S. Metho trexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001; 108: 1134–1139.

15. Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J. Rheumatol. 2005; 32: 362–365.

16. Weiss A. H., Wallace C. A., Sherry D. D. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J. Pediatr. 1998; 133 (2): 266–268.

17. Shah S. S., Lowder C. Y., Schmitt M. A. et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992; 99: 1419–1423.

18. Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur. J. Ophthalmol. 2007; 17 (5): 743–748.

19. Kilmartin D. J., Forrester J. V., Dick A. D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br. J. Ophthalmol. 1998; 82: 737–742.

20. Nussenblatt R. B., Palestine A. G., Chan C. C., Stevens G. Jr., Mellow S. D., Green S. B. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. Ophthalmol. 1991; 112 (2): 138–146.

21. Gerloni V., Cimaz R., Gattinara M., Arnoldi C., Pontikaki I., Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford). 2001; 40: 907–913.

22. Tappeiner C., Roesel M., Heinz C., Michels H., Ganser G., Heiligenhaus A. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye advance online publication. 13 June 2008; doi: 10.1038/eye.2008.174

23. Kilmartin D. J., Fletcher Z. J., Almeida J. A., Liversidge J. V., Dick A. D. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest. Ophthalmol. Vis. Ski. 2001; 42 (6): 1285–1292.

24. Zierhut M., Stubiger N., Aboalchamat W., Landerberger H., Bialasiewicz A. A., Engelmann K. Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis. Ophthalmologe. 2001; 98 (7): 647–651.

25. Greiner K., Varikkara M., Santiago C., Forrester J. V. Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe. 2002; 99 (9): 691–694.

26. Doycheva D., Deuter C., Stuebiger N., Biester S., Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br. J. Ophthalmol. 2007; 91: 180–184.

27. Teoh S. C., Hogan A. C., Dick A. D., Lee R. W. Mycophenolate mofetil for the treatment of uveitis. Am. J. Ophthalmol. 2008; 146: 752–760.

28. Sobrin L., Christen W., Foster C. S. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008; 115 (8): 1416–1421.

29. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J. et al. (Pediatric Rheumatology Collaborative Study Group). Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl. J. Med. 2000; 342: 763–769.

30. Dick A. D. Biologics in the treatment of uveitis. Curr. Opin. Ophthalmol. 2007; 18: 481–486.

31. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001; 44: 1411–1415.

32. Smith J. A., Thompson D. J., Whitcup S. M. et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005; 53: 18–23.

33. Schmeling H., Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford).

34. Richards J. C., Tay-Kearney M. L., Murray K., Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin. Experiment. Ophthalmol. 2005; 33 (5): 461–468.

35. Rajaraman R. T., Kimura Y., Li S., Haines K., Chu D. S. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006; 113 (2): 308–314.

36. Kahn P., Weiss M., Imundo L. F., Levy D. M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006; 113: 860–864.

37. Suhler E. B., Smith J. R., Wertheim M. S., Lauer A. K., Kurz D. E., Pickard T. D. et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 2005; 123: 903–912.

38. Saurenmann R. K., Levin A. V., Rose J. B. et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006; 45: 982–989.

39. Ardoin S. P., Kredich D., Rabinovich E., Schanberg L. E., Jaffe G. J. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am. J. Ophthalmol. 2007; 144: 844–849.

40. Vasquez-Cobian L. B., Flynn T., Lehman T. J. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149 (4): 572–575.

41. Biester S., Deuter C., Michels H., Kuemmerle-Deschner J., Doycheva D., Ziehrut M. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91 (3): 319–324.

42. Tynjala P., Kotaniemi K., Lindhal P., Latva K., Aalto K., Honkanen V. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47 (3): 339–344.

43. Gallagher M., Quinones K., Cervantes-Castaneda R. A., Yilmaz T., Foster C. S. Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 2007; 91 (10): 1341–1344.

44. Diaz-Llopis M., Garcia-Delpech S., Salom D., Udaondo P., Hernandez-Garfella M., Bosch-Morell F. et al. Adalimumab therapy for refractory uveitis: a pilot study. J. Ocul. Pharmacol. Ther. 2008; 24 (3): 351–361.

45. Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.

46. Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report. J. Rheumatol. 2008; 35: 1897–1898.

47. Zulian F., Balzarin M., Falcini F., Alessio M., Cimaz R. et al. Abatacept in refractory anti-TNF resistant juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010; 62: 821–825.

48. Elhai M., Deslandre C. J., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Com ment on the article by Zulian et al. Arthritis Care Res. 2011; 63: 307–310.

49. Kenawy N., Cleary G., Mewar D., Beare N., Chandna A., Pearce I. et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 2011; 249: 297–300.

50. Deschenes J., Char D. H., Kaleta S. Activated T lymphocytes in uveitis. Br. J. Ophthalmol. 1988; 72: 83–87.

51. Wang X. C., Norose K., Yano A., Ohta K., Segawa K. et al. Twocolor flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs. exogenous uveitis. Curr. Eye Res. 1995; 14: 425–433.

52. Kuek A., Hazleman B. L., Gaston J. H., Ostor A. J. K. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology. 2006; 45: 1448–1449.

53. Parikh J. C., Tawansy K. A., Rao N. A. Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology. 2008; 20 (10):1–3.

54. Miserocchi E., Pontikaki I., Modorati G., Gattinara M., Meroni P. L., Gerloni V. et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun. Rev. 2011; 11: 35–39.

55. Heiligenhaus A., Miserocchi E., Heinz C., Gerloni V., Kotaniemi K. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011; 50: 1390–1394.

56. Furst D. E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum. 2010; 39: 327–346.

57. Trachana M., Pratsidou-Gertsi P., Pardalos G., Kozeis N., Badouraki M., Kanakoudi-Tsakalidou F. et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand. J. Rheumatol. 2011; 40: 101–107.

58. Tugal-Tutkun I., Ayranci O., Kasapcopur O., Kir N. Retrospective analysis of children with uveitis treated with infliximab. J. AAPOS. 2008; 12: 611–613.

59. Kump L. I., Castaneda R. A., Andreoudi S. N., Reed G. F., Foster C. S. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006; 113 (10): 1874–1877. Epub.: 2006.

60. Thorne J. E., Woreta F., Kedhar S. R., Dunn J. P., Jabs D. A. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am. J. Ophthalmol. 2007; 143 (4): 647–655.

61. Woreta F., Thorne J. E., Jabs D. A., Kedhar S. R., Dunn J. P. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am. J. Ophthalmol. 2007; 143 (4): 647–655.